-
Sector Analysis
Disruptions to Vaccine Policy and the Future of mRNA Under the Second Trump Administration
US vaccine policy has experienced rapid changes since the start of the second Trump administration, raising concerns around future outbreaks of preventable infectious diseases, declining vaccination rates and the development of new vaccines.
-
Thematic Analysis
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
GLP 1RA therapies have shifted from treating T2D to becoming a multi indication therapy. GLP 1RAs were originally developed for type 2 diabetes (Byetta in 2005), and since 2014 they have expanded beyond T2D, starting with obesity (Saxenda) and then additional indications. GLP 1RA sales increased significantly from 2022 onwards, driven by newer therapies targeting obesity. This growth was driven by the entry and rapid uptake of Mounjaro and Wegovy (Mounjaro: ~$0.5B in 2022 to ~$23B in 2025; Wegovy: ~$0.9B...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, April 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights
Why Does ESCMID Global 2026 Matter for Your Business? ESCMID Global remains one of the most influential infectious diseases conferences for tracking emerging therapies, clinical data, and competitive developments across viral and fungal disease markets. This report provides a focused analysis of the key presentations, scientific sessions, and industry-sponsored symposia featured at ESCMID Global 2026, held in Munich, Germany between April 17 and 21. You can use this report to: Understand emerging trends in infectious disease therapeutics Analyze late-stage clinical...
-
Sector Analysis
Introduction of Drug Exclusivity in China Marks New Era for Drug Innovation
China is shifting from a generic manufacturing base to a global hub for new drug innovation. This transition is increasing the need to strengthen the patent protection system, and data exclusivity will finally be introduced in China soon.
-
Sector Analysis
Rise of High-Priced ATMPs Fuels Demand for More Flexible and Equitable HTA Mechanisms
Over the past few years, the growing influx of advanced therapy medicinal products (ATMPs) has delivered substantial advances in terms of treatment options and even cures for diseases that previously lacked effective therapies. However, these ATMPS often carry substantial development or production costs, and the need for the pharma industry to recover these costs can severely restrict their adoption by health authorities around the world. As such, demand has risen for new, more flexible, more equitable health technology assessment (HTA)...
-
Product Insights
Asthma: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Asthma - Global Clinical Trials Review, 2026" provides an overview of Asthma Clinical trials scenario. This report provides top line data relating to the clinical trials on Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Rheumatic Disorders: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Rheumatic Disorders - Global Clinical Trials Review, 2026" provides an overview of Rheumatic Disorders Clinical trials scenario. This report provides top line data relating to the clinical trials on Rheumatic Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Tuberous Sclerosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Tuberous Sclerosis - Global Clinical Trials Review, 2026" provides an overview of Tuberous Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Tuberous Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Glioblastoma Multiforme (GBM): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Glioblastoma Multiforme (GBM) - Global Clinical Trials Review, 2026" provides an overview of Glioblastoma Multiforme (GBM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.